Bagnasco Diego, Savarino Edoardo Vincenzo, Yacoub Mona-Rita, Braido Fulvio, Candeliere Maria Giulia, Giannini Edoardo, Passalacqua Giovanni, Marabotto Elisa
Allergy and Respiratory Diseases, IRCCS Policlinic San Martino, University of Genoa, 16132 Genoa, Italy.
Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy.
Pharmaceutics. 2023 Sep 21;15(9):2359. doi: 10.3390/pharmaceutics15092359.
The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis. Despite this, the association between asthma and esophagitis is still poorly known, and this is probably because of the low prevalence of each disease and the even lower association between them. Nonetheless, observations in clinical trials and, subsequently, in real life, have allowed researchers to observe how drugs acting on type 2 inflammation, initially developed and marketed for severe asthma, could be effective also in treating eosinophilic esophagitis. For this reason, clinical trials specifically designed for the use of drugs targeted to type 2 inflammation were also developed for eosinophilic esophagitis. The results of clinical trials are presently promising and envisage the use of biologicals that are also likely to be employed in the field of gastroenterology in the near future. This review focuses on the use of biologicals for type 2 inflammation in cases of combined severe asthma and eosinophilic esophagitis.
2型炎症的作用已逐渐与许多疾病相关联，包括重度哮喘、特应性皮炎、鼻息肉病、嗜酸性肉芽肿性多血管炎，以及最近发现的嗜酸性食管炎。尽管如此，哮喘与食管炎之间的关联仍鲜为人知，这可能是由于每种疾病的患病率较低，且它们之间的关联更低。尽管如此，临床试验以及随后在现实生活中的观察，使研究人员能够观察到最初开发并用于重度哮喘的作用于2型炎症的药物，如何也能有效治疗嗜酸性食管炎。因此，还针对嗜酸性食管炎开展了专门设计用于使用靶向2型炎症药物的临床试验。目前，临床试验结果很有前景，并设想在不久的将来使用也可能用于胃肠病学领域的生物制剂。本综述重点关注在重度哮喘合并嗜酸性食管炎病例中使用针对2型炎症的生物制剂。
